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In patients with cystic ﬁbrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce
the impact of infection, inﬂammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic
therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic
infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel
antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for
monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.
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Lung damage secondary to chronic infection is the main
determinant of morbidity and mortality in individuals with cystic
fibrosis (CF) [1,2]. CF individuals are highly susceptible to
bacterial infections in the respiratory tract and repeated and
intensive antibiotic therapy is required to maintain lung function
and quality of life and reduce exacerbations in infected patients.
Antibiotic therapy aimed at eradicating Pseudomonas aeruginosa,
the major bacterial pathogen in CF, after early lung infection, and
improved regimens to treat chronic P. aeruginosa infection have
played amajor role in the increasingmedian survival of CF patients
during the last decades. In 1969 CF patients in industrialized
countries had a mean survival of 14 years. By 2010 this
had improved to more than 40 years [3]. Sadly, this positive
development has not been observed in all CF centers worldwide
andmedian age at death is still in the 2nd/3rd decade. CF genotype,
different approaches to care delivery including the treatment of
infection, antibiotic selection and the mode of delivery, as well as
health care resources and the socio-economic status of the patient
[4–6] may be responsible for the different outcomes.
The objective of this consensus document is to provide
guidance for current antibiotic treatment strategies for lung
infections in CF. Here we discuss treatment courses for antibiotic
eradication therapy (AET), including the window of opportunity
in which this treatment option can be most successfully applied.
We describe treatment strategies for chronic P. aeruginosa
infection which cannot be eradicated with current antibiotics.
Measures to optimize treatment in the light of new antibiotic drug
formulations are considered and novel tools to determine the
success of antibiotic treatment courses will be highlighted. Inaddition to P. aeruginosa, sputum specimens from CF patients
generally contain many other bacterial species. We describe
developments in diagnostic methods for their detection, the
relevance of these pathogens for lung disease in CF patients and
the impact this may have on therapeutic strategies. Finally,
cost-effectiveness analyses for antibiotic treatment in CF patients
are presented and recommendations are provided for important
clinical questions. This consensus document updates related
previous documents supported by ECFS [7–9].
2. Current understanding of the pathophysiology of
CF airways infection
It is believed that the CF airways are not infected at birth and
that opportunistically pathogenic bacteria enter the lower airways
from the environment. These bacteria are able to eventually
establish a chronic presence in the airways due to impaired innate
immunity [10] and are associated with a chronic inflammatory
response. The bacteria most commonly believed to be pathogenic
in CF include P aeruginosa, Staphylococcus aureus, Hemophilus
influenzae, Stenotrophomonas maltophilia, Achromobacter
xylosoxidans, and Burkholderia species [3]. Recent microbiolog-
ical studies have demonstrated that the infection of the CF airways
is more complicated than demonstrated by standard culturing
methods, and this will be discussed later. Although we believe the
majority of these bacteria to be pathogenic, our understanding of
how best to treat each of them remains incomplete.We knowmore
about the pathogenesis and treatment of P. aeruginosa. Thus it will
receive the most attention in these recommendations.
P. aeruginosa enters the lower airways presumably by
inhalation and may transiently infect the airways of some CF
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patients are able to clear the pathogen spontaneously, or more
specifically, become culture-negative in subsequent specimens
[11–14]. However, the pathogen will persist or recur and
eventually develop into a chronic infection, which is defined as
repeatedly positive microbiological cultures and the presence of
positive serum antibodies against the pathogen [8] (Table 1).
The Leeds definition [15] classifies patients into 4 groups
according to airway culture results obtained over the last
12 months. “Chronic infection” refers to patients in whom more
than 50% of the preceding 12 months P. aeruginosa was culture
positive, and “intermittent infection” refers to patients with less
than 50% of cultures positive for P. aeruginosa. A patient is
defined as “free of P. aeruginosa” when no P. aeruginosa was
grown from samples in the previous 12 months, despite a history
of prior colonization with P. aeruginosa. “Never infected” refers
to patients in whom P. aeruginosa has never been cultured.
This definition has been evaluated in pediatric and adult CF
populations and appears to classify patients appropriately with
respect to clinical scores [15,16]. This definition is useful but
requires that frequent surveillance samples of sputum are taken
and may not be pragmatic in clinical trials.
Chronic infection results in a prolonged inflammatory response,
which is believed to cause respiratory tissue injury leading to
progressive loss of lung function. There is sufficient evidence that
eradication of early infection and prevention of chronic infection is
associated with clinical benefit. In general young CF patients
without P. aeruginosa infection and those undergoing AET have
preserved lung function (by spirometry), which only marginally
decreased over years in contrast to CF patients with chronic
P. aeruginosa infection [17,18]. For example, the decline in
“forced expiratory volume in 1 s% predicted” (FEV1%) in
CF patients who had received AET was less compared to
that in chronically infected patients (ΔFEV1/year: −1.65%
vs. −4.74%) [17]. AET studies that have followed patients
up to 18 months did not observe a lung function decline
[19,20]. In a retrospective analysis of the Toronto data base,
patients who cleared P. aeruginosa after first infection had a
similar lung function decline over the subsequent years as thoseTable 1
Definition of relevant terms.
Surveillance cultures Periodic sampling of the upper or lower airw
Colonization The presence of pathogenic bacteria in the u
Infection The presence of pathogenic bacteria in the u
Spontaneous clearance Subsequent culture of the CF upper or lowe
Intermittent infection b50% of cultures are positive for the pathog
Chronic infection N50% of cultures are positive for the pathog
or the observation of mucoidy [15].
Free of P. aeruginosa When no P. aeruginosa was grown from sam
P. aeruginosa [15].
Never infected with
P. aeruginosa
Patients in whom P. aeruginosa has never b
Eradication Subsequent cultures are free of the pathogen
Failure of eradication Subsequent cultures are positive for the path
Recurrence/re-infection Cultures of the upper or lower airways are a
of the pathogen following successful eradicawho had never been infected [21]. In studies of antibiotic
treatment of early airways infection, the failure to eradicate the
P. aeruginosa was associated with an increased risk of
pulmonary exacerbation and persistent P. aeruginosa infection
was associated with even a greater risk of exacerbation [22],
further raising the concern that persistent or recurrent infection
has a negative impact on lung health. P. aeruginosa acquisition
is associated with further deterioration in lung function in CF,
even when the pathogen is eradicated [18], suggesting that
airflow obstruction of uncomplicated CF needs to be treated,
and rigorous strategies to prevent P. aeruginosa acquisition
should be implemented.3. Current status of antibiotic prophylaxis for P aeruginosa
As P. aeruginosa infection of the CF airways may not
cause symptoms and may develop into chronic infection that
cannot be eradicated, then can prophylactic administration of
antipseudomonal antibiotics be beneficial in the prevention of
chronic airways infection by P. aeruginosa? A prospective
3-year study compared the effect of prophylactic oral ciproflox-
acin and inhaled colistin treatment with placebo on prevention
of initial P. aeruginosa infection in children with CF [23]. No
difference in the rate of acquisition of P. aeruginosa was
observed between the control and treatment groups, although
P. aeruginosa antibodies emerged earlier in the control group.
The authors concluded that a three-monthly cycled prophylactic
antibiotic therapy would not reduce the risk of initial P.
aeruginosa infection in children with CF. The risks for selecting
other pathogens, the time commitment, and the lack of cost
efficacy for this strategy may prevent further studies with
similar designs. Thus, the current data suggest that prophylactic
treatment with antipseudomonal antibiotics are not rec-
ommended to prevent P. aeruginosa infections in CF patients.
Of note, alternative strategies for primary or secondary prevention
have been evaluated [24] or are under evaluation (gargling
of avian anti-Pseudomonas IgY antibodies; EUDRACT-2011-
000801-39).ays for the purpose of identifying the presence of a CF pathogen.
pper or lower airways in the absence of an inflammatory response.
pper or lower airways associated with an inflammatory response.
r airways that is culture-negative when the previous cultures had been positive.
en of interest [15].
en of interest; this may also be defined by the presence of serum antibodies
ples in the previous 12 months, despite a history of prior colonization with
een cultured [15].
following treatment with antibiotics.
ogen following treatment with antibiotics.
gain positive for the pathogen following a period where the patient was free
tion.
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P. aeruginosa
There is strong published evidence that rigorous antibiotic
treatment of early P. aeruginosa colonization/infection is
beneficial for CF patients because it has a significantly high
eradication rate [13] and keeps the lower airways free of this
pathogen for longer periods compared to patients who are not
treated. AET is now routinely recommended in many countries
and the success of various regimens has been documented
[8,19,20,25]. Thus, AET for P. aeruginosa is recommended in
CF. Although there is evidence that in some patients a positive
culture may be transient, in most patients P. aeruginosa will
persist. Considering that a risk/benefit ratio favors AET, it
seems reasonable to initiate AET as soon as possible after a
positive P. aeruginosa respiratory culture. However, there is
currently no specific treatment strategy for the eradication of
P. aeruginosa that has been recommended. Thus,what is the best
strategy of antibiotic therapy for eradication of P. aeruginosa?
The success rates to eradicate P. aeruginosa in different AET
studies [12,13,17,19,20,26–29] ranges between 63% and 100%
(mean: 81.2%). In the open-label, randomized ELITE trial [19],
which compared the efficacy and safety of 2 regimens (28 and
56 days) of 300 mg twice daily tobramycin inhalation solution
(TIS), N90% of patients in both groups had negative cultures for
P. aeruginosa 1 month after the end of treatment and the majority
of these patients remained free from infection for up to
27 months. The median time to recurrence of P. aeruginosa in
patients' sputum/cough swab was similar in the 2 cohorts. In the
EPIC study [20], 304 children, aged 1–12 years, were random-
ized to 1 of 4 eradication treatment regimens for 18 months. The
participants, randomized to cycled therapy, received TIS
(300 mg twice a day) for 28 days, with either oral ciprofloxacin
(15–20 mg/kg twice a day) or oral placebo for 14 days every
quarter, while the participants randomized to the culture-based
therapy received the same treatment only during quarters with a
positive P. aeruginosa culture. There was no statistically
significant difference between all groups in the proportion of
P. aeruginosa positive cultures throughout the study period.
Thus, adding ciprofloxacin produced no further benefits nor
did routine periodic treatment even in the absence of positive
cultures [20].
The combination of inhaled colistin for 3 weeks–3 months of
treatment plus oral ciprofloxacin has been used successfully [30].
The efficacy of the combination of ciprofloxacin and inhaled
colistin for 3 months compared to TIS for 1 month to eradicate
early P. aeruginosa infection was compared in a real-life setting
and was similar in outcomes [31]. Furthermore, when CF patients
were assigned to inhaled colistin/oral ciprofloxacin or to inhaled
tobramycin/oral ciprofloxacin no differences in outcome between
the two arms were observed [29]. Intravenously administered
antibiotics have also been used in AET protocols [32]. In a trial
comparing oral/inhaled versus intravenous therapy, decreased
lung inflammation was observed in the latter group [33].
Although various AET protocols have demonstrated success,
none have shown clear superiority. Thus the clinician may choose
the treatment strategy that has been shown to be the mostconvenient with the same degree of success. Safety issues must
also be taken into account. AET with TIS appears to be safe in
young patients and not to cause the adverse effects seen with
recurrent parenteral administration of aminoglycosides [8,34].
Recent European Guidelines recommend the inclusion of data
from very young children in clinical studies [CHMP Guideline on
the clinical development of medicinal products for the treatment of
CF, 2011]. In patients aged 6 months to 6 years with normal renal
function, systemic exposure following inhalation of 300 mg/5 mL
of TIS was safe [35]. The use of the same doses of TIS from
infancy to adulthood is supported by the ELITE trial [19] and in
the EPIC trial [20]. A double-blind randomized multi-national
study is currently ongoing, which includes patients aged 3 months
to 7 years with the aim to provide regulatory-grade evidence of the
efficacy and safety of TIS (EUDRACT-2011-002000-32). Thus,
the current data suggest that 28 days of TIS when there is a
positive culture is a recommended treatment strategy for the
purpose of eradication of P. aeruginosa. However, because a
number of treatment protocols have been shown to be of similar
effectiveness including oral, inhalation and intravenous therapy,
and there are only few comparative studies available, the optimal
antibiotic regimen is not known.
4.1. Why is AET not always successful?
Although AET has shown mean eradication rates of
81.2%, there are some patients for whom this strategy fails
(definition Table 1). There are potential patient and pathogen
factors that may limit the ability of AET to eradicate P. aeruginosa
from CF airways. First, the patient must be adherent to the
treatment regimen in order for it to be successful. Timing may be
critical as there may be a window of opportunity after which AET
will not be successful. Although several studies suggest that
eradication of P. aeruginosa from CF airways by AET is most
successful up to 12 weeks from initial detection [36,37], this
period is not well defined and further studies are needed to better
define early, intermittent and chronic P. aeruginosa infection
(Table 1). Many factors impair the efficacy of antimicrobial drugs
and preclude the eradication of P. aeruginosa in CF, once the
infection is chronically established in the patients' airways
[38–40]. These include bacterial [39,41–47] and host factors
[8,10,48–50].
It is not known whether CF patients who fail to eradicate
P. aeruginosa after AET have more lung inflammation and/or
lung tissue injury due to the underlying CF defect or as a
consequence of bacterial infections with pathogens other than
P. aeruginosa. Maintenance of the CF patient's lung function
over extended periods of time in the presence of the persistent
pathogen in the airways is therefore a key in the antibiotic
management of chronic P. aeruginosa lung infection.
Peripheral distribution of aerosolized medications is reduced
in the presence of airway obstruction, so drug may not get to
the site of infection.
It is also possible that there is successful eradication of
infection from the lower airways, but there is rapid re-infection.
The source of the original infection may be the sinonasal
cavities, which may not be reached by inhaled antibiotics. A
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isms cultured from oral swab, sinus and BAL fluid [51] which
makes it unlikely that the sinonasal cavities initiate lower
bacterial lung infections in CF. However, other studies
contradict this hypothesis [52–54].
Finally, it is recognized that culture negativity following AET
does not necessarily mean that the pathogenwas eradicated. It may
be possible that the pathogen persists, though undetectable, after
AET in the CF airways [55]. It is not known if there is a means of
detecting the difference between true eradication and suppression
of the numbers of the viable pathogen. A serological analysis of
the EPIC AET study suggests that positive serology in CF patients
identified the participants at higher risk for re-infection with
P. aeruginosa after AET and identified CF individuals who failed
to clear P. aeruginosa infection [56]. Given the fact that AET
is considered to be the standard of care in CF, observational
studies are the only way to assess the long-term effect of this
intervention. It is important to determine whether patients who
have successfully eradicated P. aeruginosa after AET courses,
differ with regard to lung function from those patients who never
had episodes of P. aeruginosa infections and such studies should
be designed. Thus, the current data suggest that a number of
different reasons are responsible for the observation that
eradication therapy is not successful.
4.2. What is the best next strategy for the patient who has
failed AET?
The potential failure of AET argues for optimal surveillance
of P. aeruginosa in respiratory cultures (see Section 7) in orderFig. 1. The Artimino Algorithm for antibiotic eradication therapy (AET). Scheme f
(+ve: positive; −ve: negative).to know when alternative treatment options are needed. In the
EPIC trial, the subjects who did not clear P. aeruginosa after
3 weeks of treatment of the first cycle were further treated for
28 days with the study drug. The rate of treatment failure was
low (unpublished data) suggesting that repeating the initial
AET is reasonable. For those who have failed a second attempt
at eradication using inhaled and/or oral antibiotics, systemic
treatment with intravenous antibiotics may be tried. The scheme
depicted in Fig. 1 is proposed as a potential care scheme for
patients undergoing AET.
5. Optimizing antibiotic therapy for treatment of
chronic P. aeruginosa infections
Although AET has considerably decreased the prevalence of
P. aeruginosa in younger CF patients, the pathogen is still
present in the majority of older CF patients [3,5,57,58]. Chronic
suppressive antibiotics have proven successful as a treatment of
chronic airways infection in the maintenance of lung health
[59]. Tobramycin inhalation solution (TIS, Novartis) was the
first approved inhaled antibiotic, but since then there are
a number of new formulations developed for the treatment of
P. aeruginosa infections in CF patients.
5.1. Approved aerosol antibiotics
5.1.1. Tobramycin
Tobramycin is an aminoglycoside antibiotic that has long been
used as an aerosol therapy for CF. TIS was the first aerosol
antibiotic approved for CF and has been a workhorse chronicor treatment of persistent P. aeruginosa following an initial AET intervention
466 G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479medication and is included in the CF treatment guidelines [59–61]
for the suppression of P. aeruginosa infection, resulting in
improved lung function and prevention of pulmonary exacerba-
tions. The approved dose is 300 mg nebulized twice daily every
other month. TIS is available in most countries.
Tobramycin is also available in another nebulized formulation
(Bramitob®, Chiesi) [62]. The total dose is the same as for
TIS, but it is more concentrated (75 mg/mL versus 60 mg/mL)
to decrease nebulization time. In a double-blind randomized
study, 247 CF patients with chronic P. aeruginosa infection were
randomized to receive nebulized 300 mg/4 mL tobramycin or
placebo over a 24-week study period in 4-week on and off cycles.
At week 20, FEV1 was significantly increased in the intention-
to-treat population versus placebo. Treatment induced a trend
toward decreased hospitalizations, increased nutritional status,
and was well tolerated. The approved dose is 300 mg nebulized
twice daily every other month. Bramitob is currently available
only in European countries.
Tobramycin has also been developed as a dry powder
formulation (TOBI® Podhaler®, TIP™, Novartis) for the man-
agement of chronic P. aeruginosa infection in CF patients.
Tobramycin inhalation powder (TIP) capsules are formed of low
density porous particles (PulmoSphere™), which exhibit improved
flow and dispersion by inhalation via the passive T-326 dry powder
inhaler (Podhaler). The dose was developed to replicate the
pharmacokinetics of TIS [63]. Two controlled studies investigated
the efficacy and safety of TOBI Podhaler. The EAGER trial
enrolled 553 CF patients comparing TIP to TIS over 3 cycles
of treatment [64]. The EVOLVE trial, including 102 CF patients
[65], was placebo-controlled for 1 cycle followed by open label
treatment with the TOBI Podhaler for 2 additional cycles of
treatment. The Podhaler formulation displayed similar tolerability
and efficacy to TIS and significantly improved FEV1 compared
with placebo. Cough was the most frequently reported adverse
reaction related to the dry powder in both clinical studies. The
recommended dose is 112 mg (four 28 mg capsules) inhaled twice
daily in alternating cycles of 28 days on treatment followed by
28 days off treatment. TIP is currently available in some European
countries, South America, and Canada.
5.2. Aztreonam lysine for inhalation
The nebulized monobactam aztreonam lysine inhalation
solution (AZLI, Cayston®, Gilead) was approved in 2010 for
improvement of respiratory symptoms in CF patients 6 years
old and over with chronic P. aeruginosa infection. Cayston® is
delivered via the PARI eFlow platform through a portable
Altera handset which controls particle size for optimal airway
deposition, minimizes delivery time, and increases particle
delivery efficiency. Inhalation time in clinical trials averaged
2 min for each 75 mg dose [66,67]. The recommended dose is
75 mg inhaled thrice daily, with a minimum of four hours
between doses, in alternating cycles of 28 days on treatment
followed by 28 days off treatment.
In several clinical studies Cayston® has been shown to be safe
and efficacious in suppressing chronicP. aeruginosa lung infection
in CF patients [66–69]. In a randomized, placebo-controlled studyof 164 CF patients [67], Cayston significantly improved CFQ-R
Respiratory Symptoms Score (RSS) and FEV1 after one cycle of
use at 28 days, with a treatment difference compared to placebo of
9.7 points and 10.3%, respectively. In a second pivotal trial of 211
patients with CF [66], Cayston increased the median time to
need for additional antipseudomonal antibiotics for symptoms
of pulmonary exacerbation by 21 days, versus placebo. In the
open-label follow-on study of these two trials, Cayston safety and
efficacy was examined in 274 patients over 18 [68]. FEV1 values,
CFQ-R RSS, and body weight increased with each 28 day course
of Cayston, and this effect was maintained over 18 months.
No significant safety concerns were observed in studies over
12 months [70] and 18 months [68]; including no evidence of
development of antibiotic resistance.
In a 6 month active comparator trial of 273 CF patients
receiving either Cayston® or TIS, Cayston® was superior to TIS
with regard to lung function improvements, with a treatment
difference of 7.8% at 28 days and 2.7% at 24 weeks. Significant
reductions in pulmonary exacerbations and mean change in
CFQ-R RSS after 28 days of Cayston treatment were also seen,
compared to TIS. In the follow-on 6 month open-label extension
of this active comparator trial, the FEV1 response of previous TIS
subjects who were switched to Cayston® improved and was
sustained over time. Patients receiving Cayston® also gained
weight throughout the 12 month trial, compared to those who
received TIS who initially lost weight and then improved upon
switch to Cayston® [70]. Cayston® is available in the EU,
Switzerland, USA and Canada. Cayston® is licensed for use in
patients 6 years and older.
5.2.1. Colistin
The polymyxin derivative colistimethate sodium increases
Gram-negative bacterial membrane permeability causing cell
death. It has been used by inhalation for many years in CF patients
for the treatment of chronic P. aeruginosa lung infection [8].
Colobreathe® (Forest Laboratories) contains 1,662,500 IU of
colistimethate sodium inhalation powder, for the management of
chronic P. aeruginosa pulmonary infections in CF patients, aged
6 years and older [71]. In a phase III open-label trial, Colobreathe®
(125 mg twice daily) was not inferior to TIS, based on change in
FEV1% predicted after 24 weeks [71]. Colobreathe® was safe and
well tolerated in adult and pediatric subjects with CF [71].
Colobreathe® may be available in some EU countries in 2012.
5.3. Medications in development
5.3.1. Liposomal amikacin
Liposomes are biodegradable vesicles composed of single or
multiple phospholipid layers, which may protect entrapped
polycationic antibiotics, such as aminoglycosides, from inactiva-
tion by polyanionic components present in sputum, such as
mucins or DNA. In airways, liposomes can also be taken up by
macrophages. Based on this notion, liposomal amikacin for
inhalation (Arikace®, INSMED) comprised of neutral charge
liposomes has been developed to improve the penetration of the
aminoglycoside antibiotic into mucus plugs and P. aeruginosa
biofilms [72]. Clinical studies with Arikace, delivered via the
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amikacin in CF lungs [73]. The clinical pharmacokinetics and
pharmacodynamics of Arikace have been evaluated in Phase Ib
studies in 24 CF patients with chronic P. aeruginosa infection
who received 500 mg of Arikace once daily for 14 days [73].
Randomized, placebo-controlled dose escalating phase II trials in
CF patients with chronic P. aeruginosa infection showed a dose
response and indicated that Arikace, delivered at a dose of
560 mg once daily for 28 consecutive days, followed by 28 days
off drug, demonstrated superior clinical benefit compared to
placebo as measured by significant and sustained improvement in
lung function and reduction in P. aeruginosa density [74]. Also,
patients receiving Arikace showed superior improvement in their
respiratory symptoms as compared to those on placebo [74]. In
addition, Arikace® was well-tolerated [74].
5.3.2. Ciproinhale
Ciprofloxacin dry powder inhaler (DPI) has been developed
for the management of chronic P. aeruginosa infection in CF
patients. Ciprofloxacin DPI uses the PulmoSphere® technolo-
gy. Phase I studies with ciprofloxacin DPI in pediatric and adult
CF patients showed that high concentrations in the lung were
achieved with very low systemic exposure following single and
multiple dose administration. A Phase II study of ciprofloxacin
DPI, given at 2 dose levels (32.5 and 48.75 mg) twice a day for
28 days, showed significant decrease in P. aeruginosa density
compared to placebo, but did not significantly improve the
primary endpoint FEV1. There was also no significant change
in other endpoints such as respiratory symptoms or exacerba-
tions [75].
5.3.3. Levofloxacin
A novel formulation of levofloxacin, levofloxacin inhalation
solution (MP-376, Aeroquin) is being developed for the
management of chronic P. aeruginosa infection in CF patients.
As with inhaled ciprofloxacin, pharmacokinetic studies show high
levels in sputum with low systemic exposure [76]. In a phase II
study [76], 151 patients with CF were randomized to one of three
doses of MP-376 (120 mg every day, 240 mg every day, and
240 mg twice a day) or placebo for 28 days. The primary efficacy
endpoint was the change in sputum P. aeruginosa density. All
doses ofMP-376 reduced P. aeruginosa sputum density at day 28.
A dose-dependent increase in FEV1 was observed between the
240 mg MP-376 twice-daily group and placebo. A significantly
reduced need for other anti-P. aeruginosa antibiotics was
observed in all MP-376 treatment groups compared with placebo.
MP-376 was generally well tolerated relative to placebo.
5.3.4. Fosfomycin/tobramycin
A broad spectrum combination antibiotic, consisting of
fosfomycin and tobramycin, is currently developed for the
management of chronic bacterial infection in CF patients. A
phase II study has been completed (NCT00794586) in which
the safety and efficacy of 2 dose combinations of fosfomycin/
tobramycin for inhalation (FTI), following a 28-day course of
AZLI in CF patients and P. aeruginosa lung infection has been
evaluated [77].5.3.5. What is the best strategy of chronic suppressive antibiotics
for P. aeruginosa?
It is reasonable when initiating therapy for chronic airways
infection to implement a strategy as was used during drug
development; that is, an approved inhaled antibiotic should be
used in repeated cycles of 4 weeks of treatment, followed
by 4 weeks off treatment. However, the original strategy of
four-week on–off cycle of TIS [78], chosen for decreasing the
development of resistance during antibiotic therapy, has been
challenged as to whether it is the optimum treatment strategy
noting the observation of a decrease in lung function during the
off cycle [78]. The development of new antibiotic formulations
has now given clinicians and patients greater opportunity to
determine the best treatment approach. Potential strategies
could employ continuous antibiotic rather than an intermittent
approach, or to use a rotation of antibiotics rather than a single
antibiotic. Thus, it is recommended that therapeutic options for
inhaled antibiotic therapy in patients with chronic P. aeruginosa
infection include an intermittent one month-on one month-off
regime for inhaled aminoglycosides or continuous administra-
tion for inhaled colistin. In parallel with re-evaluation of all other
aspects of care, a change of the inhalation antibiotic regimen
should be considered in patients who frequently suffer from acute
exacerbations or whose lung function deteriorates rapidly.
Patients may remain on an intermittent one month-on one
month-off regime but administering another inhaled antibiotic in
the off month cycle or administering continuously inhaled
antibiotic is also rationale and may benefit those patients with
unstable disease. Current evidence from short-term studies
suggests that inhaled antibiotics are safe and that the benefit
outweighs the possible risk.
Combining different antibiotics in a given CF patient for
treating chronic P. aeruginosa lung infection may prove useful,
based on in vitro observations [79,80] and animal experiments
[80].6. Optimizing antibiotic therapy for treatment of acute
exacerbations of chronic P. aeruginosa infections
During chronic bacterial lung infection, CF patients suffer
from acute worsening of signs and symptoms, often called an
acute pulmonary exacerbation [81], a phenomenon for which
the pathophysiology has not been completely elucidated.
Antibiotics are typically a component of the treatment of a
pulmonary exacerbation. Besides maintaining lung function, a
further important goal of antibiotic therapy for chronic P.
aeruginosa infection is to prolong the time period to the next
acute respiratory exacerbation [82]. Some have recommended
systemic antibiotics for the treatment of acute exacerbations [8],
based upon the rationale that an increased production of mucus
plugs that obstruct the airways during acute exacerbations, may
allow inhaled antibiotics only to reach the bacterial pathogens
in the larger bronchi, but not in deeper areas of the respiratory
tract. There is no evidence that using inhaled antibiotics during
a course of intravenous antibiotics adds additional benefit.
Even so, inhaled antibiotics were reportedly used in one fourth
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years 2003 and 2005 [83].
A significant decrease of P. aeruginosa cell numbers and an
increase in lung function after a course of antibiotics should in
theory be linked to a considerably large bacterial population in the
patients' airways which is susceptible to the given antibiotic. Thus,
reliable in vitro antibiotic susceptibility testing should establish this
link [84]. However, substantial differences in antibiotic suscepti-
bilities between P. aeruginosa isolates with the same colony
morphology, and inconsistent results from different laboratories
question this approach [42,85,86]. A poor correlation between in
vitro susceptibility data and clinical outcome in chronically
infected CF patients after antibiotic therapy courses has been
demonstrated [87–89]. Thus, not surprisingly, a critical assessment
of the success rate of a given antibiotic treatment course using
microbiological data is often missing and rather indirect clinical
data are used to evaluate a given treatment option in this context
[90].
One quarter of CF patients treated with antibiotics for acute
exacerbations did not recover to baseline lung function [91,92]. In
one study, 57% of exacerbations were successfully treated even
though the P. aeruginosa was resistant to the antibiotics used for
treatment [92]. This leads to the question, whether antibiotic
therapy for patients with CF should be selected and rationalized
on the basis of in vitro antibiotic susceptibility testing or
whether routine susceptibility testing in P. aeruginosa should be
abandoned as there is no relation between the outcome of treatment
for exacerbations and the in vitro susceptibility for the systemic
antibiotics used.
What is the optimal antibiotic treatment of acute exacerbations
of chronic P. aeruginosa infection? There is no evidence to
support the use of inhaled antibiotics in addition to intravenously
administered antibiotics. If an antibiotic is administered by two
different routes of administration, potential additional toxicity
should be considered. For instance in cases of significant renal
impairment, inhaled aminoglycosides are frequently used for
treatment of exacerbations limiting further systemic toxicity. There
is no evidence to treat pulmonary exacerbations with inhaled
antibiotics only.6.1. What is the optimal duration of antibiotic therapy for
treatment of acute exacerbations of chronic P. aeruginosa
infection?
The length of antibiotic therapy for acute exacerbations in
CF patients, typically 10–14 days [8,81], is defined by clinical
[93] rather than by quantitative microbial data. The latter may
shed some light on the question whether the established time
frame for the treatment is justified or needs to be changed.
Thus, it is recommended that exacerbations should be treated
until symptoms resolve and lung function recovers, however
therapy should not be extended more than 3 weeks, except
under very special circumstances. Patients with multi-drug
resistant P. aeruginosa infection may require longer therapy.
Careful evaluation of the patients' clinical status is required
throughout the course of therapy.7. Current role of microbiological testing in the clinical care
of patients as well as in clinical trials
The understanding of the pathophysiology of CF airways
disease has depended on the ability to identify pathogens
through standard and novel microbiology methods. Optimal
clinical care of the CF patient requires access to a sophisticated
microbiology laboratory that is able to perform diagnostic
testing relevant to CF disease. What is evolving is our
understanding of how best to use the information derived from
the microbiology lab to provide optimal care.
As P. aeruginosa is known to be associated with worse lung
disease and current treatment strategies have shown benefit to
AET, it appears necessary to treat early infection with the
hopes of eradicating the infection (Table 1). Early acquisition
of P. aeruginosa may not cause symptoms, suggesting that
routine surveillance cultures of respiratory specimens should
be performed. Thus, what is the best method of routine
surveillance for infection of the CF airways?
Early diagnosis of P. aeruginosa lung infections may be
difficult in patients not producing sputum [1,11]. Thus,
nasopharyngeal aspirate, throat or cough swabs, sputum
induction, bronchoalveolar lavage (BAL) and serological tests
have been used for detecting infection with P. aeruginosa [8].
Antibody testing against the P. aeruginosa enzymes AP, ELA
and ExoA offers high sensitivity and specificity for the presence
of P. aeruginosa in respiratory cultures of CF patients [94].
Also other assays have been developed [95]. Early identifica-
tion of P. aeruginosa by BAL did not improve the outcome of
early eradication compared to conventional techniques [69].
P. aeruginosa serology has been demonstrated to be a useful
marker for successful eradication of the pathogen [17,27,94]
and elevated levels of specific anti-P. aeruginosa antibodies
have been shown to be a risk factor for developing chronic P.
aeruginosa infection [95]. Thus, periodic monitoring of the
patient who has never been infected or who has had successful
eradication should be performed and a period of no more than
3 months is acceptable. For those patients who have a new
infection that is treated with AET, a subsequent culture should be
obtained 2–4 weeks after completion of the antibiotics to assess
eradication. Routine serological testing is not recommended.
For those patientswith chronic infection, there is benefit to routine
monitoring, especially for those who are on suppressive antibiotic
therapy or who have had acute pulmonary exacerbations. Patients
with chronic infection do aquire new infections so regular culture is
potentially of benefit. The emergence of bacterial species in antibiotic
treated patients has been investigated using culture-basedmethods in
several clinical studies. For instance, in the ELITE trial [19], regular
monthly monitoring of respiratory cultures in the first year did not
reveal obvious trends in the emergence of non-P. aeruginosa
pathogens. However, clearly only a very small number of microbial
species have been investigated on a qualitative basis.
7.1. What is the role for antibiotic susceptibility testing?
Susceptibility testing may not be helpful for selecting
antibiotics for those patients with chronic infection as they have
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may not apply to chronic inhalation therapy because a resistant
organism according to conventional breakpoints may be still
susceptible due to the high level of antibiotic applied. Suscepti-
bility testing may not be helpful for selecting antibiotics for
treatment of acute exacerbations as patients may respond clinically
in spite of in vitro resistance. Furthermore, it remains unclear
whether specific clinical information can be used to identify
individuals at increased risk of initial management failure [91,92].
P. aeruginosa susceptibility testing should be considered for
(a) surveillance of resistant or multi-resistant P. aeruginosa
strains in combination with strain typing; (b) when a new
isolate of P. aeruginosa is identified in an individual patient;
and (c) when a change of therapy (intravenous, nebulized or
oral) is proposed because of a lack of response to treatment.
The finding of in vitro antibiotic resistance does not necessarily
indicate that treatment should be changed if the patient is
responding to the current therapy.
7.2. What is the role for quantification of bacteria?
The correct determination of bacterial cell numbers including
those for P. aeruginosa before and after a course of antibiotics is
labor intensive, particularly when culture-based strategies are
used. During chronic infection P. aeruginosa cell numbers may
reach 107 to 108 colony forming units (cfu) per gram of sputum
[96,97] and a reduction of two log orders of magnitude after
antibiotic therapy can be regarded as a major effect [96,98].
Quantitation of bacteria has been used to measure the
microbiological effect of inhaled antibiotics and a reduction in
bacterial numbers was seen in early studies of inhaled therapy
[77]. There are conflicting reports of the impact of treatment for
acute exacerbation on the bacterial load in the airways. Some
studies show an average reduction in cfu following antibiotics for
acute exacerbation [96] but others have shown a range of post
treatment bacterial load indicating that bacterial numbers do not
decrease in all patients [50,99]. Sputum specimens may differ in
viscosity and contain various bacterial phenotypes including
small colony variants, which may be difficult to culture. This can
make reliable bacterial quantitation difficult using conventional
culture based methods. At this time, quantification of bacteria
does not offer clinical utility but may still prove useful in clinical
trials.
7.3. What is the role for culture-independent microbiology?
Culture-independent diagnostic methods such as quantitative
polymerase chain reaction (qPCR) can determine total bacteria or
bacteria belonging to a particular species in clinical samples and
may avoid problems associated with culture-based strategies
[97,100–102]. The inherent problem of qPCR relates to the
inability of this approach to distinguish between living or dead
bacterial cells. Such differentiation is needed to evaluate the impact
of antibiotic therapy. This may be successfully circumvented by
tagging bacterial DNA in viable cells with propidium monoazide
photo-crosslinking before analysis or the use of RNA-based
techniques [100]. This method could also shed light on thequestion whether aP. aeruginosa-specific antibiotic therapy would
also affect cell numbers of other CF-related pathogens such as
H. influenzae [103] and S. aureus [46]. However, molecular
methods have shown a large heterogeneity of bacterial species
and their concentrations within a given sputum sample [100]
and it is not known what role these other microorganisms play
in the pathogenicity of lung infection in CF. Furthermore, the
results of culture-independent diagnostic methods may vary
with regard to the DNA isolation method used [100,104].
Finally, culture-independent techniques have not been validat-
ed and reproducibility is an important issue, it remains
uncertain whether these quantitative culture-independent
microbial diagnostic techniques should be used instead of
culture-based methods to assess the efficacy of antibiotic
therapies in CF patients or whether antibiotic therapy should be
guided by clinical and lung function parameters alone.
Culture-independent diagnostic methods for the detection of
microbial species have also demonstrated that CF sputum
specimens generally contain a larger number of different
bacterial species in high concentrations than we thought
previously [38]. For instance, several strict anaerobic species
may be present in CF sputum in numbers comparable to those
of P. aeruginosa [99]. This novel insight immediately raises the
question whether specific antibiotic therapy against P.
aeruginosa would not only affect P. aeruginosa alone but
would also change the composition of the larger microbiota in
the CF airways. Theoretically, a decrease of P. aeruginosa
during effective antibiotic therapy may provoke the growth of
other species already present in the microbiota which would
dampen the beneficial effect of the antibiotic on inflammation,
tissue destruction and lung function. On the other hand, it may
cause a significant reduction of other antibiotic susceptible
bacterial species leading to less inflammation and tissue
destruction and increased lung function. At this time,
culture-independent diagnostic methods do not offer clinical
utility but may prove useful in clinical trials.8. Current status of antibiotic treatment of other
bacterial pathogens
As noted earlier, traditional and novel methods of
microbiology have demonstrated that the airways infection in
CF is rather complex, and include multiple bacterial species.
The most common species include S. aureus, both methicillin-
susceptible (MSSA) and methicillin-resistant (MRSA), H.
influenzae, S. maltophilia, A. xylosoxidans, members of
the Burkholderia cepacia complex, and non-tuberculous
mycobacteria (NTM) species [105]. It is likely that these
microorganisms also contribute to lung inflammation and lung
tissue destruction/remodeling. As evidence is growing that
these are indeed pathogens in the CF airways, it would seem
appropriate to consider using similar treatment strategies
against them as are used to treat P. aeruginosa, including
AET and chronic antibiotic suppression. Unfortunately there
are no data to support the clinical benefit for either strategy for
these organisms.
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S. aureus has long been found in the airways of CF patients
and has been thought to be a predecessor of later infection by
P. aeruginosa and appears to be associated with increased
lower airway inflammation [106,107]. As such, some have
advocated for prophylactic therapy against S. aureus [108], a
strategy that is being recommended in the UK and other
countries [105] but has not been adopted by clinical practice
guidelines in the US [59]. This is based upon data from a
long-term placebo controlled trial in which there was no
clinical benefit for those on prophylactic antibiotic therapy
after 7 years of treatment [109].
MRSA strains have been increasingly recognized among
CF patients in the last decade [3,110]. In a recent epidemi-
ological study in Italy Penton Valentine Leukocidin (PVL)-
negative MRSA strains with a high resistance rate to
clindamycin and moderate resistance to trimethoprim/
sulpha-methoxazole were detected in 31.4% of Italian CF
patients. Recent data suggest that MRSA strains are markers
of more severe disease in CF patients but are not more
virulent than MSSA strains [11–116]. Acquisition of MRSA
has been associated with hospitalization, the F508del
genotype and the presence of bronchiectasis [116]. For treatment
of S. aureus, recommended drugs, doses and regimens are given
in Table 2.
Other methods of infection control would also seem prudent.
In countries with a policy of segregation and eradication of first
infection of MRSA, chronic infection with MRSA is rare [117].
It seems that the rates of MRSA in CF patients parallel those
in the overall community, suggesting that differing rates in
different countries do not reflect different treatment modalities
in the CF patient population.Table 2
Recommended antibiotics for therapy against Staphylococcus aureus in patients wit
Antibiotic Route of administration
Flucloxacillin Oral
Dicloxacillin Oral, i.v.
Fusidic acid Oral, i.v.
Clindamycin Oral, i.v.
Rifampicin Oral, i.v.
Vancomycin I.v.
Teicoplanin I.v.
Linezolid Oral, i.v. (b5 years)
Linezolid Oral, i.v. (N5 years)
Cotrimoxazole (trimetoprim compound) Oral
Amoxicillin/clavulanic acid Oral
Cefuroxime/axetil Oral
If rifampicin or fusidic acid or clindamycin or macrolides such as azithromycin are u
considered in combination with e.g., dicloxacillin or flucloxacillin. For pathogens diffic
be used. Linezolid is an expensive drug and clinical experience is limited. Linezolid has
associated with neuropathy. Other drugs listed should be used for combination therapy o
and therefore influences the normal flora. It can be used when both H. influenzae an
comorbidities. Always check for drug–drug interactions, especially with fusidic acid a8.2. S. maltophilia and A. xylosoxidans
S. maltophilia prevalence rates still vary considerably between
CF centers with a mean prevalence rate of up to 25% in single
centers [118] with rapidly increasing prevalence in others [119].
Studies have presented conflicting data regarding the clinical
significance of S. maltophilia [120,121]. Chronic infection
associated with the development of an immune response against
the organism, predicts more exacerbations [122], but not more
progression in decline of lung function [122]. Relatively little is
known about the clinical significance of A xylosoxidans in CF
and more studies are needed to determine when treatment should
be given and which antibiotics should be used. Recommended
antibiotics for therapy against S. maltophilia and A. xylosoxidans
infections in patients with CF are given in Table 3.
8.3. Burkholderia cepacia complex strains
Other antibiotic resistant bacterial pathogens, associated with
CF patients, include the Burkholderia cepacia complex (Bcc), a
group of at least 17 closely related bacterial species [123], from
which B. cenocepacia, B. multivorans and B. dolosa are the most
prevalent in CF. Due to its high virulence, effective antibiotics to
treat Bcc-infected CF patients are urgently needed [124]. Few
trials have systematically examined the antibiotic treatment of
Bcc infection in CF patients.
Recently, a large randomized, controlled trial enrolled 101 CF
patients to evaluate the safety and efficacy of Cayston® versus
placebo in BCC-infected CF patients. Subjects received Cayston®
or placebo continuously every month in addition to standard
therapy for the first 6 months of the study. No difference in FEV1
was demonstrated between the two groups. No benefit was
realized in the 6 month cross over phase [125]. Recommendedh CF.
Dose
(mg/kg/day)
Administrations
per day
Maximum daily dose
(g)
Oral IV
100 3–4 4.5 12.0
50 3–4 4.0 12.0
25–50 2–3 2.0 2.0
20–40 2–4 1.8 1.8
15–20 2 0.6 0.6
40 2 – 2.0
10 1 – 0.8
30 3 1.2 1.2
20 2 1.2 1.2
8–10 2 0.32 –
50–100 3 4.0
20–30 2 1.0
sed, a high risk to develop resistance is present. Therefore these drugs should be
ult to treat such asMRSA, rifampicin+fusidic acid or rifampicin+clindamycin can
a high barrier to the development of resistance. Long-term therapy with linezolid is
f MRSA. Augmentin (amoxicillin+clavulanic acid) is a broad-spectrum antibiotic
d S. aureus are cultured [172]. Drug doses may need to be adapted according to
nd rifampicin.
Table 3
Recommended antibiotics for therapy against S. maltophilia and A. xyloxidans in patients with CF ⁎.
Antibiotic Route of
administration
Dose
(mg/kg/day)
Administrations
per day
Maximum daily dose
(g)
Oral IV
Minocyclin Oral 2–3 1–2 0.2 –
Doxycyclin Oral 2–3 1 0.2 –
Sulfamethoxazol/trimetoprim Oral, i.v. 50–100+10–20 2–4 0.48 0.48
Ceftazidime I.v. 150–200 3 – 12.0
Meropenem I.v. 100–150 3 – 6
Colistin ** I.v. 2–5 2–4 – 0.48
Tobramycin I.v. 5–10 1–3 – 0.48
Ciprofloxacin Oral, i.v. 20–30 2–3 1.5 1.2
Aztreonam I.v. 150–250 3 – 8.0
Ticarcillin/clavulanic acid I.v. 200–300/6–10 4–6 – 16.0 (ticar comp)
Piperacillin/tazobactam I.v. 200–240/25–30 3–4 – 16.0 (piperacillin
comp)
⁎ These species are resistant to many antibiotics and easily become resistant to antibiotics during treatment. Susceptibility testing must therefore guide the choice of
antibiotics and combination therapy is usually recommended: Aztreonam/ticarcillin/clavulanic acid combination therapy because of synergism against S. maltophilia.
Tetracyclines should not be used in children. Tobramycin drug levels need to be measured. Drug doses may need to be adapted according to comorbidities. Always
check for drug–drug interactions.
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are given in Table 4.
8.4. NTM species
Increasingly NTM species, in particular M. avium-
intracellulare complex,M. chelonae andM. abscessus complex
are diagnosed in airway specimens of mainly older CF patients
[126]. Because infection is associated with an accelerated
clinical decline [126], and clinical improvements have been
observed after anti-mycobacterial therapy, these pathogens
should be treated when associated with a clinical deterioration
or when the patient does not respond to the antibiotic treatment
against other microorganisms detected in parallel in respiratory
cultures [127]. However, there is no treatment regimen that has
been demonstrated to be routinely successful in deriving a
clinical benefit or eradicating the infection.
8.5. What is the optimal treatment strategy of NTM infections in
CF patients?
Diagnosis and treatment guidelines have been published
[ATS guidelines] for NTM infections in general, and for CF in
particular. Treatment of NTM infection is a serious commit-
ment, requiring multiple antibiotics and for an extended
treatment period [128] (Tables 5, and 6). Novel therapies are
being considered. For example, the possibility that liposomes
can be taken up by macrophages may provide Arikace® with
enhanced activity against intracellular NTM species such as
M. avium-intracellulare complex, M. chelonae and M. abscessus
which are found in airway specimens of CF patients [126,129].
Of note, the long-term use of the macrolide azithromycin has
become an accepted therapy for patients with CF [59].
Azithromycin has multiple beneficial effects on inflammation
and lung physiology [38,130–132] and reduces P. aeruginosa
biofilm formation and quorum sensing regulated extracellularvirulence factors [133,134]. It is recommended that chronic
macrolides are withheld in patients with NTM infection in order to
prevent selection of resistant pathogens [59]. Recent concern that
macrolides may increase the risk of acquiring NTM infections is
based upon in vitro studies of human macrophages where
azithromycin prevented lysosomal acidification, thereby impairing
autophagic and phagosomal degradation and as a consequence
inhibited intracellular killing of mycobacteria within macro-
phages, resulting in chronic infection with NTM in mice [135].
However, this phenomenon has not been observed in clinical CF
trials with azithromycin [136].
8.6. Anaerobic species
The potential role for anaerobic species in the pathogenesis
of CF airways disease has become of greater interest as
culture-independent analysis of CF respiratory specimens has
revealed the presence of strict anaerobic species [97,99,137–140].
Many strict anaerobic bacteria are antibiotic resistant [99,141].
Studies show that a higher diversity of strict anaerobes is
associated with a younger age [142], and better lung function
[143]. The major reason why clinicians have not specifically
treated anaerobes is because the clinical significance of these
species remains unclear. For Prevotella intermedia, however, in
vitro data suggest that the pathogenmay contribute to lung disease
in CF patients [144]. The demonstration that P. intermedia
produces cytotoxins and provokes inflammation in vitro suggests
that it causes airway damage, which if demonstrated in vivowould
facilitate the decision for antibiotic treatment.
8.7. Other microbial pathogens
Other commonly identified microbial pathogens present in
airways of CF patients include Aspergillus fumigatus, for which
increasing prevalence is clearly associated with the use of
inhaled antibiotics [145]. A. fumigatus may cause severe
Table 4
Recommended antibiotics for therapy against B. cepacia complex in patients with CF ⁎.
Antibiotic Route of
administration
Dose
(mg/kg/day)
Administrations
per day
Maximum daily dose
(g)
Oral IV
Doxycyclin Oral 2–3 1 0.20 –
Sulfamethoxal/trimetoprim Oral, i.v. 50–100+10–20 2–4 0.48 ⁎⁎ 0.48 ⁎⁎
Ceftazidime I.v. 150–200 3 – 12.0
Meropenem I.v. 120 3 – 6.0
Tobramycin I.v. 5–10 1–3 – 0.48
Aztreonam I.v. 150–250 3 – 8.0
Ticarcillin/clavulanic acid I.v. 200–300/6–10 4–6 – 16.0 ⁎⁎⁎
Piperacillin/tazobactam I.v. 200–240/25–30 3–4 – 16.0 ⁎⁎⁎
⁎ These species are resistant to many antibiotics and easily become resistant to antibiotics during treatment. Susceptibility testing must therefore guide the choice
of antibiotics and combination therapy is usually recommended. For B. cepacia complex three i.v. drugs are recommended.
⁎⁎ Trimethoprim compound.
⁎⁎⁎ Ticarcillin and piperacillin compound. Drug doses may need to be adapted according to comorbidities. Always check for drug–drug interactions.
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pergillosis (ABPA) in 2–7.8% of CF patients [146,147].
In summary, the presence of many other bacterial species
besides P. aeruginosa in CF airways may represent a target for
therapy, because they are either directly pathogenic or they may
increase the virulence of other pathogens [148] or inhibit
antibiotics thereby diluting their effects on P. aeruginosa [100].
The path from identification of the organism to management
decisions requires epidemiological studies that demonstrate the
role the organism plays in the pathogenesis of disease and
the observation of clinical benefit from treatment interventions
designated specifically at the pathogen. Early epidemiological
studies of these pathogens have begun to inform us that
these are indeed pathogens, but we lack clinical studies of
intervention and such studies are clearly needed.
9. Comparative efficacy of inhaled antibiotics in CF and
endpoints in clinical trials
There is a perceived need for additional antibiotic choices
for the management of CF airways disease. As there are no new
antibiotic classes being developed, new options for inhaled
antibiotics are the most likely new development and some have
been discussed earlier (Section 5). The clinical need is due to
the fact that some patients cannot tolerate current available
options, they have become refractory to the current therapy or
the treatment burden results in poor adherence and thus,
reduced efficacy [149–151]. Technological advances, such asTable 5
Recommended antibiotics for therapy against Mycobacterium avium complex
infections in patients with CF.
Antibiotic Route of
administration
Dose
Clarithromycin Oral 500–1000 mg/d
Azithromycin Oral 250–300 mg/d
Ethambutol Oral 15 mg/kg/d
Rifabutin Oral 150–300 mg/d
Rifampicin Oral 450–600 mg/d
Amikacin I.v. 15 mg/kg/day
Aim for eradication: 12 months of negative sputum cultures while on therapy.faster and smarter nebulizers and dry powder formulations,
offer great opportunity, but there is also a need for additional
drug classes, as current approved formulations include only an
aminoglycoside, a monobactam, and a polymyxin.
The challenge to further development of new aerosol antibiotic
options is how best to study them. In general, the clinical trials for
developing new inhaled antibiotics are designed either as
superiority studies versus placebo. However, when such studies
require extended periods of no antibiotic, they are no longer
considered ethical for patients. Although non-inferiority studies
can be performed, given the relatively small treatment benefits it
is difficult to agree on an optimal non-inferiority margins.
Non-inferiority trials typically require large numbers of patients
making such studies more difficult to conduct.
In the light of novel antibiotic formulations for CF patients,
which bring important patient benefits for the same clinical
efficacy, as reported in clinical trials, it is important to further
discuss how these benefits can be valued and included in a
comparative effectiveness research reflecting real-life benefits. In
the context of a clinical trial setting, the patients' adherence is
generally high, whereas in the real-world, rates of adherence and
persistence rates are much lower and the efficacy of a drug can be
therefore decreased [149,152]. In addition, it is important to
explore how patient satisfaction due to new delivery systems can
be translated in real-life increased compliance, reduced treatment
burden and better clinical outcomes.
9.1. How do we assess the response to antibiotic treatment in
CF patients?
Regulators such as the EMA [153] and the FDA rely
particularly on phase III trials with clinical endpoints such as
improvement in FEV1 [154]. However, short-term increases in
lung function observed in antibiotic trials a decade ago [77] are
currently rarely observed as patients are better treated and rates of
lung function decline are drastically reduced [68,155]. These
developments make FEV1 difficult to use as an endpoint in CF
trials with antibiotics. Therefore, other techniques and clinical
endpoints have been suggested which are currently under
investigation including several lung imaging techniques and
Table 6
Recommended antibiotics for therapy against Mycobacterium abscessus
infections in patients with CF.
Antibiotic Route of administration Dose
Clarithromycin Oral 500–1000 mg/d
Azithromycin Oral 250–300 mg/d
Cefoxitin: i.v. 200 mg/kg/d ⁎
Amikacin I.v. 15 mg/kg/d ⁎⁎
Inhaled 250–500 mg twice daily
Meropenem: I.v. 40 mg/kg ⁎⁎⁎
Tigecycline: I.v. 50 mg twice daily ⁎⁎⁎⁎
Linezolid Oral 600 mg twice daily
Interferon gamma s.c. 25–50 μg/m2, 2 or 3 times
weekly
⁎ Divided every 8 h, max 12 g.
⁎⁎ Inhaled 250–500 mg twice daily.
⁎⁎⁎ Divided every 8 h, max 6 g.
⁎⁎⁎⁎ t1/2=40 h. In case of hepatotoxicity 100 mg every other day. Comment:
aim for stable disease although reported cases show a decline in lung function
despite maintenance therapy.
473G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479several sputum biomarkers. Novel bacteriological tools may
provide valuable information in phase II studies which may have
an impact for the design and conduct of phase III trials.
Other benefits, such as improvement in health-related
quality of life (HRQoL), which includes improvement in
respiratory symptoms, satisfaction, convenience, reduced
administration time of the different antibiotics and their
delivery device, should be considered in making treatment
choices. CF patients have a high treatment burden due to an
increased number of drugs and they need to execute lengthy
procedures every day for the administration of their medications.
A drug, with a novel technology which provides a decrease in the
administration time and that eases the burden for the same efficacy
and safety, is therefore highly beneficial. Assessment of the
patient's perspective of symptom improvement, adherence,
convenience and persistence, and their reported increase in
HRQoL and satisfaction should be part of the treatment decision
making [156]. Patient reported outcomes (PROs) have been used
for regulatory approval and are considered increasingly important
as secondary outcome parameters [156–158].10. Economic evaluation of antibiotics in CF
In an increasing number of countries decisions to reimburse
medicines, medical devices and medical procedures are based
on health economic assessments (e.g. cost effectiveness
analyses, CEA, or cost-utility analyses, CUA) and budget
impact estimation [159,160]. The results of such evaluations,
whereby different treatment alternatives are compared are
typically summarized in an incremental cost-effectiveness ratio
(ICER). The denominator of ICER reflects the incremental
health gain which is the combined increase in life expectancy
and in HRQoL, expressed as quality adjusted life-years
(QALY) gained from the better intervention. The numerator
in ICER reflects the incremental cost of obtaining that health
gain. Note that the incremental cost already accounts for thepotential savings of the intervention and thus represents a net
cost of the intervention [161].
Guidelines have been developed which provide recommen-
dations for the conduct of economic evaluations in order to
improve their validity and reliability [162,163]. In addition,
comparative effectiveness research is gaining importance in
evaluating real-world benefits of different strategies. This
concept is defined as “the comparison of effective interventions
among patients in typical patients care settings, with decisions
tailored to individual patient's needs” [164].
There have been relatively few economic evaluations of
antibiotic treatments in CF, with three different areas of interest:
(a) the economic value of home- versus hospital-based intrave-
nous therapy, (b) assessment of cost-effectiveness of inhaled
antibiotics, specifically TIS and AZLI and (c) the relationship
between costs, including patient co-payments and out of pocket
expenses, and adherence and (d) the economic value of antibiotic
eradication therapy.10.1. Intravenous antibiotics
A CEA of using home-based and hospital-based treatment
with intravenous antibiotics for respiratory exacerbations in
adults with CF has been carried out in UK [165]. During one
year, 454 courses of intravenous antibiotics in 116 CF patients
were retrospectively analyzed (213 courses were hospital-based
and 214 courses were home-based). Lung function as measured
by FEV1 increased in hospital-treated patients and decreased in
home-treated patients after one year, suggesting that hospital-
based treatment was more effective and most costly in hospital
than home-based treatment. The mean ICER of hospital versus
home-based treatment was £46,098 over 1-year of treatment.
However, in Sweden home intravenous antibiotic treatment is
successfully practiced since 1985 [166,167]. Decisions to treat
patients at home or in the hospital are driven by various medical
and social aspects.10.2. Inhaled antibiotics
At the time of this document development the only published
economic evaluations available were for TIS. Economic evalua-
tions of TIS have been conducted in the UK from the perspective
of the National Health Service (NHS) [168] and in Canada from
the perspective of the Canadian Health Service in Ontario and
Quebec [169]. In Canada, the acquisition cost of TIS was
estimated to be CA$8602 over a 24-week period. Mean offsets in
direct medical costs for all patients treatedwith TIS versus placebo
were CA$4916 in Quebec and CA$4055 in Ontario.
In the UK, in all patients the cost of TIS was partially offset
by savings of £3719 per year compared with placebo in 2001
[168]. This was primarily because of a reduction in the mean
number of days spent in the hospital (7.8 days), resulting in
savings of £2345 and a reduction in the mean number of days'
treatment with intravenous antibiotics (6.4 days), resulting in
savings of £1344. The net direct cost was £6292 per year, based
on a TIS acquisition cost to the NHS of £10,010 in 2001. In
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resulting in a net cost versus placebo of £3830.
Recently, a cost-effectiveness analysis of the AZLI–TIS
active comparator study was performed using a Markov
model with health states defined principally by FEV1 %
predicted levels [170]. Over 3 years, AZLI use was associated
with increased life-years, reduced number of hospitalizations,
increased QALYs, and a subsequent cost savings of over $6000
over TIS.10.3. Antibiotic eradication therapy
A CEA was done to compare costs for AET and for treatment
of chronic P. aeruginosa lung infection in CF [17,171]. The 47
AET-treated patients received a total of 104 antibiotic therapy
courses over 7 years, costing in total €34,681 (€105.4/patient/
year). The 47 age-matched, chronically P. aeruginosa-infected
CF patients received 683 courses in 7 years costing in total
€1,767,025 (€5371/patient/year). Thus, treating CF patients
with AET is recommended, because costs for AET are
significantly lower compared with those needed to treat
chronically infected CF patients. Various AET study designs
revealed similar success rates and cost-effectiveness analyses for
this strategy are recommended to harmonize current regimens
and to implement a standard operating procedure for AET in
different CF centers. Questions concerning the window of
opportunity to eradicate the pathogen in a given CF patient, the
choice and doses of the antibiotic(s), the length of the treatment
course, and the prophylactic use of antibiotics for AET, could be
answered in such analyses.
Although few economic analyses were performed to
compare different treatment strategies (AET, inhaled antibi-
otics), future discussions are needed. The limited number of
comparative studies and the non-inferiority designs allow for
cost-minimization analysis and it is difficult to conduct proper
CEAs or CUAs for inhaled antibiotic treatments in CF
patients. Even more challenging is the model framework and
the model inputs. Generally the model uses data from clinical
trials. However, almost all trials are of short duration (not
longer than 3 cycles of treatment) and do not use hard
outcomes such as survival. It is difficult to design models with
lifetime horizon based on short-term trials. In the case of CF,
economic model work needs to be done to link FEV1%
predicted outcomes to survival. This link could be helpful to
design a model over a lifetime horizon and provide a better
understanding of the economic value of treating a P.
aeruginosa infected CF patient with a given inhaled antibiotic
versus alternative drugs.
Discussion among experts involving clinicians and health
economists with regard to the design of economic evaluations
will help to find optimal solutions. Furthermore, comparative
effectiveness research should be developed also to compare the
real-life benefits of different CF therapies. In particular,
research should address multiple stakeholders' demands,
should demonstrate real-world value of the CF drug and should
apply transparent and harmonized protocols.11. Members of the Consensus Study Group
Gerhild Angyalosi, M.D. Ph.D, Novartis Pharma AG, Novartis
Campus, CH-4056 Basel, Switzerland, Phone: +41 61 32 44789,
Email: gerhild.angyalosi@novartis.com; Baroukh Assael,
M.D., Ospedale Civile Maggiore, Piazzale Stefani 1, 37126
Verona, Italy, phone +39 3397356268, E-mail: baroukh.
assael@ospedaleuniverona.it, Scott Bell, MBBS, MD, FRACP,
Thoracic Medicine, The Prince Charles Hospital, Rode Road,
Chermside, Q, 4032, Australia, Phone: (+61) 7 31394406,
Fax: (+61) 7 31394510, E-mail: Scott_Bell@health.qld.gov.
au, Diana Bilton M.D., FRCP, Department of Respiratory
Medicine, Royal Brompton Hospital, Sydney Street, London
SW3 6NP, Email: a.howard@rbht.nhs.uk, Kris De Boeck,
M.D., Pediatric Pulmonology, Dept Pediatrics, University
Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium,
phone +32 16343856 or +32 16343831, Fax no.: +32 16343842,
E-mail: christiane.deboeck@uz.kuleuven.ac.be, Andrew Bush,
M.D., Imperial College and Royal Brompton Hospital, London,
UK, Phone: +44 (0)20 7352 8121 x2255, Email: a.bush@
imperial.ac.uk, Preston W. Campbell, III, M.D., Cystic Fibrosis
Foundation, 6931 Arlington Rd, Bethesda, MD 20814. E-mail:
pcampbell@cff.org, Antonino Cattaneo, Ph.D., Chiesi
Farmaceutici S. P. A., Via Palermo, 26/A, 43122 Parma, phone
+39 0521 2791, Email: a.cattaneo@chiesigroup.com, Klaus
Dembowsky, M.D., Polyphor Ltd. Hegenheimermattweg 125,
CH-4123 Allschwil, Switzerland, Email: klaus.dembowsky@
polyphor.com, Gerd Döring Ph.D., Eberhard-Karls-Universtät,
Institute of Medical Microbiology and Hygiene, Wilhelmstrasse
31, D-72074 Tübingen, Germany, phone 49-7071 298 2069,
Email: gerd.doering@med.uni-tuebingen.de, Pavel Drevinek,
M.D., Department of Paediatrics, Department of Medical
Microbiology, 2nd Faculty of Medicine, Prague, Czech Republic
Email: pavel.drevinek@Lfmotol.cuni.cz, Christine Dubois,
ECFS, Viborg, Denmark, phone +458667 6260 Email:
christine.dubois@ecfs.eu, Irmgard Eichler, M.D., European
Medicines Agency, 7 Westferry Circus, Canary Wharf, London
E14 4HB, UK, phone: +44 207 523 7338 Email: irmgard.
eichler@ema.europa.eu, J. Stuart Elborn, M.D., Centre for
Infection and Immunity, Queens University, Lisburn Rd, Belfast
BT9 7AB, Northern Ireland, UK, phone +44 28 90 263683, Fax
no.: +44 28 90 263546, E-mail: stuart.elborn@belfasttrust.hscni.
net, Patrick A. Flume, M.D., Medical University of South
Carolina Dept of Medicine, 96 Jonathan Lucas St., P.O. Box
250630, Charleston, SC 29425, Phone: (843) 792-9219, Email:
flumepa@musc.edu, Juliet E. Foweraker, Department of Micro-
biology, Papworth Hospital, Papworth Everard, Cambridge CB3
8RE, United Kingdom. Phone: 44 1480 830541. Fax: 44 1480
364780. E-mail: juliet@gjfuller.co.uk, Charles Gallagher M.B.,
FRCPI, FRCP, FCCP, University College Dublin and St
Vincent's University Hospital, Email: V.hearn@st-vincents.ie,
Dr. Silvia Gartner, Unidad de Neumología Pediátrica y Fibrosis
Quística, Hospital Universitari Vall d'Hebron. Area Materno
InfantilPg. Vall d'Hebron, Barcelona, Spain, phone: 349 34 89 31
97, Email: sgartner@vhebron.net, David E. Geller, M.D., Florida
State University College of Medicine, Orlando, FL 32806, USA,
email: degeller@earthlink.net, Martin Goldman, M.D., Forest
475G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479Laboratories UK Ltd, Riverbridge House, Anchor Boulevard,
Crossways, Dartford, Kent DA2 6SL, UK phone +44 (0)1322
421824, Email: MGoldman@forest-labs.co.uk, Christopher
H. Goss, M.D., MS, FCCCP. University of Washington Medical
Center 1959 N.E. Pacific, Campus Box 356522 Seattle, WA
98195-6522, USA, phone (206) 616-1058, Email: goss@u.
washington.edu, Renu Gupta, M.D. Insmed Incorporated,
Princeton Corporate Plaza, 11 Deer Park Drive, Suite 117,
Monmouth Junction, NJ 08852-1923, Phone: (732) 997-4526,
Email: rgupta@insmed.com, Harry G Heijerman, M.D., Depart-
ment of Pathology, Ziekenhuis Leyenburg, afd. Longziekten,
Centrum voor Cystic Fibrosis, Leyweg 275, 2545 CH Den Haag,
Email: hgmheij@knmg.nl, Noreen Henig, MD ,Gilead Sciences,
Foster City, CA, USA, phone: (+1) 6505225267, E-mail: noreen.
henig@gilead.com; Mark Higgins, M.D., Novartis Horsham
Research Centre, Horsham, West Sussex, UK, Email: mark.
higgins@novartis.com, Lena Hjelte, M.D., Stockholm Cystic
Fibrosis Center, Karolinska University Hospital Huddinge B59,
Stockholm, Sweden, 141 86 phone: 0046858587359, email:
Lena.Hjelte@karolinska.se, Niels Hoiby, M.D., Rigshospitalet
Department of Clinical Microbiology, Juliane Maries Vey 22,
2100 København, Dänemark, email: hoiby@hoibyniels.dk,
Roberto Jongejan, Forest Nederland, Newtonlaan 115, 3584
BHUtrecht, The Netherlands phone: +31 (0)30 210 6260, Email:
Rjongejan@forestlabs.nl, Martin Knoch, M.D., PARI Pharma
GmbH, Lochhamer Schlag Gräfelfing, Germany, Phone +49 (0)
89 742846-59, Email: m.knoch@pari.de, Michael W. Konstan,
M.D. Department of Pediatrics, Rainbow Babies and Children's
Hospital, Case Western Reserve University School of Medicine,
Cleveland, Ohio, USA, phone: (216) 844-3884, Email: michael.
konstan@case.edu, Dr. Marianne S. Muhlebach, Dept. Pediatrics
CB 7217 University of North Carolina at Chapel Hill, NC
27599-7217, USA, phone: (919) 966-1401, Email: marianne_
muhlebach@med.unc.edu, Pim W. F. Nieuwenhuizen, PhD,
Gilead Sciences Netherlands B. V., phone: +31 207 183666 pim.
nieuwenhuizen@gilead.com, Michael D. Parkins, M.D., 3330
Hospital Drive NW, Calgary, AB Canada T2N 4N1, 403-210-
7913, phone: 403-270-2772, mdparkin@ucalgary.ca, Tacjana
Pressler, M.D., Department of Pediatrics, Afsnit 5003,
Rigshospitalet, Juliane Maries Vej, 2100 Copenhagen, Denmark,
phone: +45 3545 1298, Fax no: +33 (0)1 40 03 47 55, Email
pressler@mail.dk, Alexandra L. Quittner, Ph. D, Department of
Psychology, 5665 Ponce de Leon Blvd, University of Miami,
Coral Gables, FL 33146-2070; E-mail: aquittner@miami.edu,
Felix Ratjen M.D., PhD, FRCPC, Head, Division of Respiratory
Medicine, University of Toronto, Hospital for Sick Children, 555
University Avenue, Toronto Ontario, M5G 1X8, Phone (416) 813
6167, Email: felix.ratjen@sickkids.ca, Bonnie W. Ramsey, M.D.,
Department of Pediatrics, University of Washington School of
Medicine, Seattle Childrens Research Institute, 2001 West 8th
Street, Seattle, WA 98125, USA. E-mail: bonnie.ramsey@
seattlechildrens.org, Alan Smyth, M.D., Division of Respiratory
Medicine, Clinical Sciences Building, Nottingham City Hospital,
Hucknall Road, Nottingham NG5 1PB, United Kingdom, phone:
0115 823 1703 or 1702; Email: alan.smyth@nottingham.ac.uk,
Ruth Thieroff-Ekerdt, M.D., Aptalis Pharma, 100 Somerset
Corporate Blvd., Bridgewater, New Jersey 08807 USA, Phone:(908) 429-4479, ext. 4065 Email: rekerdt@aptalispharma.com,
Elizabeth Tullis, M.D., Department of Medicine, Faculty of
Medicine, University of Toronto, Bond Wing, 30 Bond Street,
Toronto, ON M5B 1W8, phone:416-864-5406 Email: tullise@
smh.toronto.on.ca, Cornelis K. van der Ent, MD, PhD, Department
of Pediatric Pulmonology, University Medical Center Utrecht,
Utrecht, The Netherlands; E-mail: k.vanderent@umcutrecht.nl,
Carlos Vazquez, M.D., Department of Pediatrics, Cruces Hospital
and Basque University School of Medicine, Bilbao, 48903 Basque
Country, Spain, carlos.vazquezcordero@osakidetza.net, Claire E.
Wainwright, M.D., Queensland Children's Respiratory Centre,
Royal Children's Hospital, Brisbane, Australia, Email:
claire_wainwright@health.qld.gov.au.
References
[1] Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R,
et al. Early pulmonary infection, inflammation, and clinical outcomes in
infants with cystic fibrosis. Pediatr Pulmonol 2001;32:356-66.
[2] Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL.
Pseudomonas aeruginosa and other predictors of mortality and morbidity
in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91–100.
[3] Cystic fibrosis foundation patient registry 2009 annual data report.
Bethesda, MD, USA: Cystic Fibrosis Foundation; 2010.
[4] Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW,
Wagener JS, et al. Association of socioeconomic status with the use of
chronic therapies and healthcare utilization in children with cystic
fibrosis. J Pediatr 2009;155:634-9.
[5] McCormick J, Mehta G, Olesen HV. Comparative demographics of the
European cystic fibrosis population: a cross-sectional database analysis.
Lancet 2010;375:1007-13.
[6] Taylor-Robinson D, Whitehead W, Diderichsen F, Vebert Olesen H,
Pressler T, Smyth RS, Diggle P. Understanding the natural progression in
%FEV1 decline in patients with cystic fibrosis: a longitudinal study.
Thorax 2012;67:860-6.
[7] Döring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A,
et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic
fibrosis: a European consensus. Eur Respir J 2000;16:749-67.
[8] Döring G, Hoiby N, for the Consensus Study Group. Early intervention and
prevention of lung disease in cystic fibrosis: a European consensus. J Cyst
Fibros 2004;3:67-91.
[9] Heijerman H, Westerman Elsbeth, Conway S, Touw D, Döring G. Inhaled
medication and inhalation devices for lung disease in patients with cystic
fibrosis: a European consensus. J Cyst Fibros 2009;8:295-315.
[10] Döring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride
channel mutations provoke lung disease. Cell Microbiol 2009;11:208-16.
[11] Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M,
et al. Longitudinal assessment of Pseudomonas aeruginosa in young
children with cystic fibrosis. J Infect Dis 2001;183:444-52.
[12] Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B,
Döring G, et al. Placebo-controlled, double-blind, randomized study of
aerolized tobramycin for early treatment of Pseudomonas aeruginosa
infection in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
[13] Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker
A, et al. Significant microbiological effect of inhaled tobramycin in
young children with cystic fibrosis. Am J Respir Crit Care Med
2003;167:841e9.
[14] Van Ewijk BE, Wolfs TFW, Fleer A, Kimpen JLL, Van der Ent CK.
High Pseudomonas aeruginosa acquisition rate during acute respiratory
infection in healthy and cystic fibrosis children. Thorax 2006;61:641-2.
[15] Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM.
Evaluation of a new definition for chronic Pseudomonas aeruginosa
infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29-34.
[16] Proesmans M, Balinska-Miskiewicz W, Dupont L, Bossuyt X,
Verhaegen J, Høiby N, et al. Evaluating the “Leeds criteria” for
476 G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir
J 2006;27:937-43.
[17] Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early
eradication therapy against Pseudomonas aeruginosa in cystic fibrosis
patients. Eur Respir J 2005;26:1-4.
[18] Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, et al.
Lung function from infancy to the preschool years after clinical diagnosis
of cystic fibrosis. Am J Respir Crit Care Med 2008;178:42-9.
[19] Ratjen F, Munck A, Kho P, Angyalosi G. ELITE Study Group.
Treatment of early Pseudomonas aeruginosa infection in patients with
cystic fibrosis: the ELITE trial. Thorax 2010;65:286-91.
[20] Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M,
Kronmal R, et al. Comparative efficacy and safety of 4 randomized
regimens to treat early Pseudomonas aeruginosa infection in children
with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-56.
[21] Amin R, Lam M, Dupuis A, Ratjen F. The effect of early Pseudomonas
aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr
Pulmonol 2011;46:554-8.
[22] Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M,
Retsch-Bogart G, Treggiari MM, et al. Initial Pseudomonas aeruginosa
treatment failure is associated with exacerbations in cystic fibrosis.
Pediatr Pulmonol 2012;47:125-34.
[23] Tramper-Stranders GA, van der Ent CK,Molin S, Yang L, Hansen SK, Rau
MH, et al. Initial Pseudomonas aeruginosa infection in patients with cystic
fibrosis: characteristics of eradicated and persistent isolates. Clin Microbiol
Infect 2011, http://dx.doi.org/10.1111/j.1469-0691.2011.03627.x.
[24] Döring G, Meisner C, Stern M, for the Flagella Vaccine Trial Study
Group. A double-blind randomized placebo-controlled phase III study of
a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.
PNAS 2007;104:11020-5.
[25] Cantón R, Cobos N, De Gracia J, Baquero F, Honorato J, Gartner S.
Antimicrobial therapy of pulmonary pathogenic colonisation and
infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin
Microbiol Infect 2005;11:690-703.
[26] Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas
aeruginosa colonisation in cystic fibrosis by early treatment. Lancet
1991;338:725-6.
[27] Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on
early Pseudomonas aeruginosa colonisation in patients with cystic
fibrosis. Lancet 2001;358:983-4.
[28] Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S,
Accurso FJ, et al. Duration of treatment effect after tobramycin solution
for inhalation in young children with cystic fibrosis. Pediatr Pulmonol
2007;42:610-23.
[29] Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F.
Early antibiotic treatment for Pseudomonas aeruginosa eradication in
patients with cystic fibrosis: a randomised multicentre study comparing
two different protocols. Thorax 2012;67:853-9.
[30] Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas
aeruginosa infection. J Cyst Fibros 2005;4(Suppl. 2):49-54.
[31] Proesmans M. Comparison of two treatment regimens for eradication of P
aeruginosa infection in children with cystic fibrosis. J Cyst Fibros in press.
[32] Lillquist YP, Cho E, Davidson AG. Economic effects of an eradication
protocol for first appearance of Pseudomonas aeruginosa in cystic
fibrosis patients: 1995 vs. 2009. J Cyst Fibros 2011;10:175-80.
[33] Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT,
et al. Inhaled versus systemic antibiotics and airway inflammation in
children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol
2010;45:281-90.
[34] Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection,
administration and monitoring. Drugs 1994;47:902-13.
[35] Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R,
et al. Serum and lower respiratory tract drug concentrations produced by
tobramycin for inhalation in young children with cystic fibrosis. J Pediatr
2001;139:572-7.
[36] Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy
for intermittent Pseudomonas aeruginosa airway infection in cystic
fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-30.[37] Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B.
Approach to eradication of initial Pseudomonas aeruginosa infection in
children with cystic fibrosis. Pediatr Pulmonol 2007;42:751-6.
[38] Rogers GB, Hoffman LR, Döring G. Novel concepts in evaluating
antimicrobial therapy for bacterial lung infections in patients with cystic
fibrosis. J Cyst Fibros 2011;10:387-400.
[39] Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in
cystic fibrosis. Future Microbiol 2010;5:1663-74.
[40] del Pozo JL, Patel R. The challenge of treating biofilm-associated
bacterial infections. Clin Pharmacol Ther 2007;82:204-9.
[41] Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR,
D'Argenio DA, et al. Genetic adaptation by Pseudomonas aeruginosa to
the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;3:
8487-92.
[42] Foweraker JE, Laughton CR, Brown DF, Bilton D. Comparison of
methods to test antibiotic combinations against heterogeneous
populations of multiresistant Pseudomonas aeruginosa from patients
with acute infective exacerbations in cystic fibrosis. Antimicrob Agents
Chemother 2009;53:4809-15.
[43] Döring G, Parameswaran GI, Murphy TF. Differential adaptation of
microbial pathogens to airways of patients with cystic fibrosis and
chronic obstructive pulmonary disease. FEMS Microbiol Rev 2010,
http://dx.doi.org/10.1111/j.1574-6976.2010.00237 [28 MAY 2010].
[44] Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas
aeruginosa strains producing high levels of persister cells in patients with
cystic fibrosis. J Bacteriol 2010;192:6191-9.
[45] Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic
resistance of bacterial biofilms. Int J Antimicrob Agents 2010;35:322-32.
[46] Bjarnsholt T, Østrup Jensen P, Jakobsen TH, Phipps R, Nielsen AK,
Rybtke MT, et al. Quorum sensing and virulence of Pseudomonas
aeruginosa during lung infection of cystic fibrosis patients. PLos One
2010;5:e10115 [doi:10.1371].
[47] Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ,
et al. Pseudomonas aeruginosa population diversity and turnover in cystic
fibrosis chronic infections. Am J Respir Crit Care Med 2011;183:1674-9.
[48] Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL,
Chmiel JF, et al. Inflammatory and microbiologic markers in induced
sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit
Care Med 2003;168:1471-5.
[49] Ciofu O, Mandsberg L, Bjarnsholt T, Wassermann T, Høiby N. Genetic
adaptation of P. aeruginosa during chronic lung infection of patients
with cystic fibrosis: strong and weak mutators with heterogenous genetic
backgrounds emerge in mucA and/or lasR mutants. Microbiology
2010;156:1108-19.
[50] Yang L, Jelsbak L, Marvig RL, Damkiæra S, Workmana CT, Rau MH,
et al. Evolutionary dynamics of bacteria in a human host environment.
PNAS 2011;108:7481-6.
[51] Muhlebach MS, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW.
Are lower airway or throat cultures predictive of sinus bacteriology in
cystic fibrosis? Pediatr Pulmonol 2006;41:445-51.
[52] Mainz JG, Hentschel J, Schien C, Cramer N, Pfister W, Beck JF, et al.
Sinonasal persistence of Pseudomonas aeruginosa after lung transplan-
tation. J Cyst Fibros 2012;11:158-61.
[53] Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, et al.
Evolution and diversification of Pseudomonas aeruginosa in the
paranasal sinuses of cystic fibrosis children have implications for chronic
lung infection. ISME J 2011, http://dx.doi.org/10.1038/ismej.2011.83.
[54] Johansen HK, Aanaes K, Pressler T, et al. Colonization and infection of
the paranasal sinuses in cystic fibrosis patients is accompanied by a
reduced PMN response. J Cyst Fibros in press, http://dx.doi.org/10.1016/
j.jcf.2012.04.011.
[55] Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gérardin
M, Brahimi N, et al. Genotypic characterization of Pseudomonas
aeruginosa strains recovered from patients with cystic fibrosis afterinitial
and subsequent colonization. Pediatr Pulmonol 2001;32:288-92.
[56] Anstead, M, Heltshe S, Khan U, et al. Pseudomonas aeruginosa serology
and risk for re-isolation in the EPIC trial. J Cyst Fibros in press, http://dx.
doi.org/10.1016/j.jcf.2012.08.001.
477G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479[57] Bellis G, Cazes MH, Parant A, Gaimard M, Travers C, Le Roux E, et al.
Cystic fibrosis mortality trends in France. J Cyst Fibros 2007;6:179-86.
[58] Guidelines to the ECFSPR. http://www.ecfs.eu/projects/efcs-patient-
registry/guidelines.
[59] Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel Jr PJ,
Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines. Chronic
medications for maintenance of lung health. Am J Respir Crit Care Med
2007;176:957-69 [Epub 2007 Aug 29].
[60] Flume PA, Mogayzel PJ, Robinson KA, Rosenblatt RL, Quittell L,
Marshall BC, et al. Cystic fibrosis pulmonary guidelines: treatment of
pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.
[61] Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in
cystic fibrosis. Cochrane Database Syst Rev 2011;3:CD001021.
[62] Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov
N, et al. Formulation of aerosolized tobramycin (Bramitob) in the treatment
of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a
double-blind, placebo-controlled, multicenter study. Paediatr Drugs
2007;9(Suppl. 1):21-31.
[63] Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel
tobramycin inhalation powder in cystic fibrosis subjects: pharmacoki-
netics and safety. Pediatr Pulmonol 2007;42:307-13.
[64] Konstan MW, Flume PA, Kappler M, Chirond R, Higgins M, Brockhaus
F, et al. Safety, efficacy and convenience of tobramycin inhalation
powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros
2011;10:54-61.
[65] Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.
Tobramycin inhalation powder for P. aeruginosa infection in cystic
fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8.
[66] McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ,
Montgomery AB. Inhaled aztreonam lysine for chronic airway
Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care
Med 2008;178:921-8.
[67] Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS,
Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine
for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-32.
[68] Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS,
Montgomery AB, et al. An 18-month study of the safety and efficacy of
repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr
Pulmonol 2010;45:1121-34.
[69] Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB,
Cheney J, et al. Effect of bronchoalveolar lavage-directed therapy on
Pseudomonas aeruginosa infection and structural lung injury in children
with cystic fibrosis: a randomized trial. JAMA 2011;306:163-71.
[70] Assael BM, Pressler T, Bilton D, Fayond M, Fischer R, Chiron R, et al.
Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A
comparative efficacy trial. J Cyst Fibros in press, http://dx.doi.org/10.
1016/j.jcf.2012.07.006.
[71] Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience
of colistimethate sodium dry powder for inhalation (Colobreathe® DPI) in
cystic fibrosis patients: a randomised study Thorax in press.
[72] Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R,
et al. Biofilm penetration, triggered release and in vivo activity of inhaled
liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
J Antimicrob Chemother 2008;61:859-68.
[73] Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A,
et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal
amikacin for inhalation in cystic fibrosis patients with chronic
pseudomonal infection. Antimicrob Agents Chemother 2009;53:
3847-54.
[74] Clancy JP, Minic P, Dupont L, Goss CH, Quittner AL, Lymp JF, et al.
Full analyses of data from two phase II blinded and placebo-controlled
studies of nebulized liposomal amikacin for inhalation (Arikace™) in the
treatment of cystic fibrosis patients with chronic Pseudomonas
aeruginosa lung infection. Pediatr Pulmonol 2010;45:299-300.
[75] Dorkin H, Criollo M, Reimnitz P, Alder J, Hampel B. Randomized,
double-blind, placebo-controlled, multicenter study to evaluate the safety
and efficacy of inhaled ciprofloxacin compared with placebo in patients
with cystic fibrosis. Pediatr Pulmonol 2011(Suppl. 34):A235.[76] Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ.
Levofloxacin inhalation solution (MP-376) in patients with cystic
fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med
2011;183:1510-6 [Epub 2011 Feb 25].
[77] Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM,
McKevitt M, et al. Fosfomycin/tobramycin for inhalation in patients with
cystic fibrosis with pseudomonas airway infection. Am J Respir Crit
Care Med 2012;185:171-8.
[78] Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB,
Williams-Warren J, et al. Intermittent administration of inhaled tobramycin
in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
[79] Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to
the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is
linked to metabolically active cells, and depends on the pmr and
mexAB-oprM genes. Mol Microbiol 2008;68:223-40.
[80] Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, et al.
Colistin/tobramycin combinations are superior to monotherapy
concerning the killing of biofilm P. aeruginosa. J Infect Dis October
13 2010;202, http://dx.doi.org/10.1086/656788.
[81] Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3-Management.
Thorax 2008;63:180-4.
[82] Amadori A, Atonellia A, Balteria I, Schreiber A, Bugianib M, De Rose
V. Recurrent exacerbations affect FEV1 decline in adult patients with
cystic fibrosis. Respir Med 2009;103:407-13.
[83] Moskowitz S, Sliva S, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA,
et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr
Pulmonol 2008;43:874-81.
[84] Razvi S, Saiman L. Microbiology of cystic fibrosis: role of the clinical
microbiology laboratory, susceptibility and synergy studies and infection
control. In: Hodson M, Geddes D, Bush A, editors. Cystic Fibrosis. 3rd
ed. London: Hodder Arnold; 2007. p. 123-33.
[85] Ciofu O, Fussing V, Bagge N, Koch C, Høiby N. Characterization of paired
mucoid/non-mucoid Pseudomonas aeruginosa isolates fom Danish cystic
fibrosis patients: antibiotic resistance, beta-lactamase activity and riboprinting.
J Antimicrob Chemother 2001;48:391-6.
[86] Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic
variability of Pseudomonas aeruginosa in sputa from patients with
acute infective exacerbation of cystic fibrosis and its impact on the
validity of antimicrobial susceptibility testing. J Antimicrob Chemother
2005;55:921-7.
[87] Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D,
et al. Combination antibiotic susceptibility testing to treat exacerbations
of cystic fibrosis associated with multiresistant bacteria: a randomised,
double-blind, controlled clinical trial. Lancet 2005;366:463-71.
[88] Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM,
Rosenbluth D, et al. Randomized trial of biofilm testing to select
antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2010;6:
184-92.
[89] Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL.
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical
response to parenteral antibiotic administration: lack of association in
cystic fibrosis. Chest 2003;123:1495-502.
[90] Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr
Opin Pulm Med 2011;17:442-7.
[91] Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss
CH. Failure to recover to baseline pulmonary function after cystic
fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:
627-32.
[92] Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for
pulmonary exacerbation treatment failures in cystic fibrosis patients
chronically infected with Pseudomonas aeruginosa. Chest Aug 11 2011
[Epub ahead of print].
[93] VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing
time to pulmonary function benefit following antibiotic treatment of
acute cystic fibrosis exacerbations. Respir Res 2010;11:137.
[94] Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G.
Diagnostic value of serum antibodies in early Pseudomonas aeruginosa
infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42:249-55.
478 G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479[95] Pressler T, Karpati F, Granström M, Knudsen PK, Lindblad A, Hjelte L,
et al. Diagnostic significance of measurements of specific IgG antibodies
to Pseudomonas aeruginosa by three different serological methods. J
Cyst Fibros 2009;8:37-42.
[96] Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of
sputum Pseudomonas aeruginosa density by antibiotics improves lung
function in cystic fibrosis more than do bronchodilators and chest
physiotherapy alone. Am Rev Respir Dis 1990;141:914-21.
[97] Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath
SJ, et al. Use of culture and molecular analysis to determine the effect
of antibiotic treatment on microbial community diversity and
abundance during exacerbation in patients with cystic fibrosis. Thorax
2011, http://dx.doi.org/10.1136/thx.2010.137281.
[98] Meyer KC, Lewandoski JR, Zimmerman JJ, Nunley D, Calhoun WJ,
Dopico GA. Human neutrophil elastase and elastase/alpha1-antiprotease
complex in cystic fibrosis — comparison with interstitial lung disease
and evaluation of the effect of intravenously administered antibiotic
therapy. Am Rev Respir Dis 1991;144:580-5.
[99] Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach
MS, et al. Detection of anaerobic bacteria in high numbers in sputum
from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:
995–1001.
[100] Rogers GB, Marsh P, Stressmann AF, Allen CE, Daniels TVW, Carroll
MP, et al. The exclusion of dead bacterial cells is essential for accurate
molecular analysis of clinical samples. Clin Microbiol Infect 2010;16:
1656-8.
[101] Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM,
et al. The adult cystic fibrosis airway microbiota is stable over time and
infection type, and highly resilient to antibiotic treatment of exacerbations.
PLoS One 2012;7:e45001, http://dx.doi.org/10.1371/journal.pone.0045001
[Epub 2012 Sep 26].
[102] Blainey PC, Milla CE, Cornfield DN, Quake SR. Quantitative analysis of
the human airway microbial ecology reveals a pervasive signature for
cystic fibrosis. Sci Transl Med 2012;4:153ra130.
[103] Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B. Comparison of
a beta-lactam alone versus beta-lactam and an aminoglycoside for
pulmonary exacerbation in cystic fibrosis. J Pediatr 1999;134:413-21.
[104] Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community
dynamics in cystic fibrosis airway. PNAS 2012;109:5809-14.
[105] Fibrosis Trust Cystic. Antibiotic Treatment for Cystic Fibrosis— Report of
the UKCystic Fibrosis AntibioticWorking Group 3rd ed.; 2009 [http://www.
cftrust.org.uk/aboutcf/publications/consensusdoc/Antibiotic_treatment_for_
Cystic_Fibrosis.pdf].
[106] Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS,
et al. Impact of Pseudomonas and staphylococcus infection on
inflammation and clinical status in young children with cystic fibrosis.
J Pediatr 2009;154:183-8.
[107] Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, et al.
Inflammatory responses to individual microorganisms in the lungs of
children with cystic fibrosis. Clin Infect Dis 2011;53:425-32.
[108] Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. , The
Cochrane LibraryOxford: Update Software; 2001.
[109] Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic
prophylaxis in infants and young children with cystic fibrosis: a
randomized controlled trial. J Pediatr 2002;140:299-305.
[110] Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin
resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis.
Arch Dis Child 2001;84:160-2.
[111] Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP.
Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1
decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814-21.
[112] Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS,
Waltz DA, et al. The impact of incident methicillin resistant
Staphylococcus aureus detection on pulmonary function in cystic
fibrosis. For the investigators and coordinators of the epidemiologic
study of cystic fibrosis. Pediatr Pulmonol 2008;43:1117-23.
[113] Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N,
Boyle MP. Association between respiratory tract methicillin-resistantStaphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303:
2386-92.
[114] Muhlebach MS, Miller M, Lavange LM, Mayhew G, Goodrich JS,
Miller MB. Treatment intensity and characteristics of MRSA infection in
CF. J Cyst Fibros 2011;10:201-6.
[115] Goss CH, Muhlebach MS. Staphylococcus aureus and MRSA in cystic
fibrosis. J Cyst Fibros 2011;10:298-306.
[116] Vanderhelst E, De Meirleir L, Verbanck S, Pierard D, Vincken W,
Malfroot A. Prevalence and impact on FEV1 decline of chronic
methicillin-resistant Staphylococcus aureus (MRSA) infection in patients
with cystic fibrosis. A single-center, case–control study of 165 patients. J
Cyst Fibros 2012;11:2-7.
[117] Dutch CF database. http://www.ncfs.nl/index.php?id=002546.
[118] Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for
emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr
Pulmonol 2000;30:10-5.
[119] De Vrankrijker AMM, Wolfs TFW, Van der Ent CK. Challenging and
emerging pathogens in cystic fibrosis. Paediatr Respir Rev 2010;11:
246-54.
[120] Karpati F, Malmborg A-S, Alfredsson H, Hjelte L, Strandvik B. Bacterial
colonisation with Xanthomonas maltophilia— A retrospective study in a
cystic fibrosis patient population. Infection 1994;22:258-63.
[121] Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas
maltophilia does not reduce survival of patients with cystic fibrosis. Am J
Respir Crit Care Med 2002;166:356-61.
[122] Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, et al.
Stenotrophomonas maltophilia in cystic fibrosis: serologic response and
effect on lung disease. Am J Respir Crit Care Med 2011;183:635-40.
[123] LiPuma J. The changing microbial epidemiology in CF. Clin Microbiol
Rev 2010;23:299-323.
[124] Nørskov-Lauritsen N, Johansen HK, Fenger MG, Nielsen XC, Pressler T,
Olesen HV, et al. Unusual distribution of Burkholderia cepacia complex
species in Danish cystic fibrosis clinics may stem from restricted
transmission between patients. J Clin Microbiol 2010;48:2981-3.
[125] Tullis E, Burns J, Retsch-Bogart G, Bresnik M, Henig N, Lewis S, et al.
Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients
with chronic Burkholderia species (BURK) infection: final results from a
randomized, placebo-controlled trial. J Cyst Fibros 2012;11(S1):S11.
[126] Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, et al.
Nontuberculous mycobacteria. Am J Respir Crit Care Med 2003;167:835-40.
[127] Fauroux B, Delaisi B, Clement A, Saizou C, Moissenet D, Truffot-Pernot
C, et al. Mycobacterial lung disease in cystic fibrosis: a prospective
study. Pediatr Infect Dis J 1997;16:354-8.
[128] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C,
Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment,
and prevention of nontuberculous mycobacterial diseases. Am J Respir
Crit Care Med 2007;175:367-416.
[129] Esther CR, Henry MM, Molina PL, Leigh MW. Nontuberculous
mycobacterial infection in young children with cystic fibrosis. Pediatr
Pulmonol 2005;40:39-44.
[130] Feldman C, Anderson R, Theron A, Mokgobu I, Cole PJ, Wilson R. The
effects of ketolides on bioactive phospholipid-induced injury to human
respiratory epithelium in vitro. Eur Respir J 1999;13:1022-8.
[131] Yousef AA, Jaffe A. The role of azithromycin in patients with cystic
fibrosis. Paediatr Respir Rev 2010;11:108-14.
[132] Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M,
Hocevar-Trnka J, et al. Effect of azithromycin on pulmonary function in
patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a
randomized controlled trial. JAMA 2010;303:1707-15.
[133] Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C.
Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.
Antimicrob Agents Chemother 2001;45:1930-3.
[134] Pérez-Martínez I, Haas D. Azithromycin inhibits expression of the
GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas
aeruginosa. Antimicrob Agents Chemother 2011;55:3399-405.
[135] Renna M, Schaffner C, Brown K, Shang S, Henao Tamayo M, Hegyi K,
et al. Azithromycin blocks autophagy and may predispose cystic fibrosis
patients to mycobacterial infection. J Clin Invest 2011;121:3554-63.
479G. Döring et al. / Journal of Cystic Fibrosis 11 (2012) 461–479[136] Fleet J, Guha K, Piper S, Banya W, Bilton D, Hodson ME. A
retrospective analysis of the impact of azithromycin maintenance therapy
on adults attending a UK cystic fibrosis clinic. J Cyst Fibros in press,
http://dx.doi.org/10.1016/j.jcf.2012.05.010.
[137] Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD.
Bacterial diversity in cases of lung infection in cystic fibrosis patients:
16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA
terminal restriction fragment length polymorphism profiling. J Clin
Microbiol 2003;41:3548-58.
[138] Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD.
Characterization of bacterial community diversity in cystic fibrosis lung
infections by use of 16s ribosomal DNA terminal restriction fragment
length polymorphism profiling. J Clin Microbiol 2004;42:5176-83.
[139] Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V,
et al. Use of 16S rRNA gene profiling by terminal restriction fragment
length polymorphism analysis to compare bacterial communities in
sputum and mouthwash samples from patients with cystic fibrosis. J Clin
Microbiol 2006;44:2601-4.
[140] Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, et al.
Discerning the complexity of community interactions using a Drosophila
model of polymicrobial infections. PLoS Pathog 2008;4:e1000184.
[141] Worlitzsch D, Rintelen C, Bohm K, Wollschläger B, Merkel N,
Borneff-Lipp M, et al. Antibiotic-resistant obligate anaerobes during
exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009;15:
4544-60.
[142] Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, et al. Airway
microbiota and pathogen abundance in age-stratified cystic fibrosis patients.
PLoS One 2010;5:e11044, http://dx.doi.org/10.1371/journal.pone.0011044.
[143] Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SV, Knapp
AA, et al. Relationship between cystic fibrosis respiratory tract bacterial
communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Environ Microbiol 2010;12:1293-303.
[144] Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, Krismer B, et al.
Relative contribution of Prevotella intermedia and Pseudomonas
aeruginosa to lung pathology in airways of cystic fibrosis patients.
Thorax 2010;65:978-84.
[145] De Vrankrijker AM, van der Ent CK, van Berkhout FT, Stellato RK,
Willems RJ, Bonten MJ, et al. Aspergillus fumigatus colonization in
cystic fibrosis: implications for lung function? Clin Microbiol Infect
2011;17:1381-6.
[146] Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary
aspergillosis in cystic fibrosis: reported prevalence, regional distribution,
and patient characteristics. Chest 1999;116:639-46.
[147] Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J,
et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A
European epidemiological study. Eur Respir J 2000;16:464-71.
[148] Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG.
A polymicrobial perspective of pulmonary infections exposes an
enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA
2008;105:15070-5.
[149] Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA.
Longitudinal association between medication adherence and lung health
in people with cystic fibrosis. J Cyst Fibros 2011;10:258-64 [Epub 2011
Mar 31].
[150] Modi AC, Quittner AL. Barriers to treatment adherence for children with
cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol
2006;31:846-58.
[151] Sawicki GS, Rasouliyan LR, McMullen AH, Wagener JS, McColley SA,
Pasta DJ, et al. Longitudinal assessment of health-related quality of life in
an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol
2011;46:36-44.
[152] Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell
LM. Adherence with tobramycin inhaled solution and health care
utilization. BMC Pulm Med 2011;11:5.[153] CHMP Guideline on the clinical development of medicinal products for
the treatment of CF. http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2009/12/WC500017055.pdf; 2009.
[154] U.S. Department of Health and Human Services, Food and Drug
Administration. Guidance for Industry: Developing Antimicrobial Drugs -
General Considerations for Clinical Trials (draft guidance). http://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm070983.pdf; 1998.
[155] Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in
young adults with cystic fibrosis. Thorax 2006;61:155-7.
[156] Quittner AL, Alpern AN, Kimberg CI. Integrating patient-reported
outcomes into rearch and clinical practice. In: Wilmott RW, Boat T, Bush
A, Chernick V, Deterding R, Ratjen F, editors. Kendig & Chernick's
Disorders of the Respiratory Tract in Children. 8th edition. Oxford: UK:
Elsevier Inc.; 2012. p. 251-60.
[157] Abbott J, Hart A, Havermans T, Matossian A, Goldbeck L, Barreto C,
et al. Measuring health-related quality of life in clinical trials in cystic
fibrosis. J Cyst Fibros 2011;10:82-5.
[158] Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc
Am Thorac Soc 2007;4:378-86.
[159] Bambha K, Kim WR. Cost-effectiveness analysis and incremental
cost-effectiveness ratios: uses and pitfalls. Eur J Gastroenterol Hepatol
2004;16:519-26.
[160] Simoens S. Factors affecting the cost effectiveness of antibiotics.
Chemother Res Pract 2011, http://dx.doi.org/10.1155/2011/249867.
[161] Annemans L. Health economics for non-economists: an introduction to
the concepts, methods and pitfalls of health economic evaluations.
Academia Press; 2011.
[162] Drummond M, O'Brien B, Stoddart G, Torrance G, Drummond M,
O'Brien B, et al. Methods for the economic evaluation of health care
programmes. Oxford University Press; 1987.
[163] National Institute for Clinical Excellence. Guide to the methods of
technology appraisal. London: NICE; 2004.
[164] Sox HC, Greenfield S. Comparative effectiveness research: a report from
the Institute of Medicine. Ann Intern Med 2009;151:203-5.
[165] Thornton J, Elliot RA, Tully MP. Clinical and economic choices in the
treatment of respiratory infections in cystic fibrosis: comparing hospital
and home care. J Cyst Fibros 2005;4:239-47.
[166] Strandvik B, Hjelte L, Malmborg A-S, Widén B. Home intravenous
antibiotic treatment in cystic fibrosis. Acta Paediatr Scand 1992;81:
340-4.
[167] Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum
BN, et al. Differences in prevalence and treatment of Pseudomonas
aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. J
Cyst Fibros 2009;8:135-42.
[168] Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic
evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cyst
Fibros 2003;2:120-8.
[169] LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O. Savings in
direct medical costs from the use of tobramycin solution for inhalation in
patients with cystic fibrosis. Clin Ther 2000;22:140-51.
[170] Schechter MS. Benchmarking to improve the quality of cystic fibrosis care.
Curr Opin Pulm Med 2012;18:596-601, http://dx.doi.org/10.1097/MCP.
0b013e328358d533.
[171] Baumann U, Stocklossa C, Greiner W, Graf von der Schulenburg J-M,
von der Hardt H. Cost of care and clinical condition in paediatric cystic
fibrosis patients. J Cyst Fibros 2003;2:84-90.
[172] Dalbøge C, Pressler T, Høiby N, Nielsen K, Johansen HK. A cohort study
of the Copenhagen CF centre eradication strategy against Staphylococcus
aureus in patients with CF. J Cyst Fibros 2012, http://dx.doi.org/10.1016/
j.cf.2012.06.005.
